Inuvair

Formoterol fumarate dihydrate, the active ingredient in Inuvair, is a combination inhaled corticosteroid and long‑acting β2‑agonist presented as a metered‑dose inhaler for inhalation use. It is indicated for the treatment of asthma and chronic obstructive pulmonary disease in adults. It delivers both bronchodilation and anti‑inflammatory effects, helping to improve lung function and reduce exacerbations.

GNH USA supplies Inuvair as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Inuvair, a combination inhaled corticosteroid and long‑acting β2‑agonist, acts on the obstructive airway disease pathway.

Asthma: improves symptom control and reduces risk of exacerbations. COPD: enhances lung function and decreases frequency of flare‑ups. Bronchial hyperresponsiveness: provides sustained bronchodilation and anti‑inflammatory action to stabilize airway reactivity.

Inhaled use of Inuvair may be associated with a range of adverse reactions.

Common Side Effects: - Throat irritation or soreness - Cough - Hoarseness or voice change - Oral candidiasis (fungal infection) - Headache

Serious or Rare Side Effects: - Paradoxical bronchospasm - Severe allergic reaction (anaphylaxis) - Adrenal suppression with long‑term high‑dose use

Before prescribing Inuvair, clinicians should consider several precautionary measures.

Assess asthma control: ensure patient is on appropriate maintenance therapy before adding. Monitor for oral thrush: advise rinsing mouth after inhalation. Use with a spacer: improves drug delivery and reduces local side effects. Avoid abrupt discontinuation: taper to prevent loss of control. Review cardiac history: β2‑agonists may affect heart rate and rhythm. Store at room temperature: keep in original packaging, protect from moisture and heat.

Inuvair can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Beta‑blockers: may diminish bronchodilator effect and precipitate bronchospasm. - Diuretics (e.g., furosemide): increase risk of hypokalemia when combined with β2‑agonists. - MAO inhibitors: potential for severe hypertension with sympathomimetic activity.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (ketoconazole, ritonavir): may raise systemic exposure to beclometasone. - Theophylline: concurrent use may require serum level monitoring due to additive bronchodilator effect.